A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Open accessThe DOI matches its Crossref record; 121 of the 127 references it cites were found in a registry or an index; 18 of the 86 sources its claims cite were checked for support.
Abstract
The process of stopping antipsychotics may be causally related to relapse, potentially linked to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity. Therefore, the risk of relapse on cessation of antipsychotics may be minimized by more gradual tapering. There is converging evidence that suggests that adaptations to antipsychotic exposure can persist for months or years after stopping the medication-from animal studies, observation of tardive dyskinesia in patients, and the clustering of relapses in this time period after the cessation of antipsychotics. Furthermore, PET imaging demonstrates a hyperbolic relationship between doses of antipsychotic and D2 receptor blockade. We, therefore, suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): ie, reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance. Some patients may prefer to taper at 10% or less of their most recent dose each month. This process might allow underlying adaptations time to resolve, possibly reducing the risk of relapse on discontinuation. Final doses before complete cessation may need to be as small as 1/40th a therapeutic dose to prevent a large decrease in D2 blockade when stopped. This proposal should be tested in randomized controlled trials.
Overview
CoChat Summary
TL;DR
The paper proposes that antipsychotics should be tapered gradually over months or years and in a hyperbolic manner—reducing by fractions of the most recent dose that correspond to roughly even decrements in D2 receptor blockade—to minimize withdrawal-related relapse. It argues this hypothesis is supported by converging evidence on dopamine supersensitivity, tardive dyskinesia, relapse clustering after cessation, and PET dose-occupancy relationships, but it has not been tested in randomized controlled trials.
Key findings
- The authors recommend reductions of one quarter or one half of the most recent antipsychotic dose, approximately equivalent to 5 or 10 percentage-point reductions in D2 blockade, at intervals of 3–6 months, titrated to individual tolerance; some patients may prefer reductions of 10% or less of the most recent dose each month.
- Final doses before complete cessation may need to be as small as 1/40th of a therapeutic dose to avoid a large drop in D2 blockade when stopped.
- A meta-analysis cited by the authors found relapse rates over the next year of 77% after abrupt stopping, 57% after stopping over 1–2 weeks, 47% after 3–10 weeks, and 31% after tapering longer than 10 weeks.
- PET data show a hyperbolic dose–D2 occupancy relationship; for haloperidol, linear dose reductions from 4 mg produce increasingly large occupancy drops: 3.5 percentage points from 4 to 3 mg, 6.1 from 3 to 2 mg, 13.7 from 2 to 1 mg, and 55.7 from 1 to 0 mg.
Methods
- Narrative review and hypothesis paper synthesizing animal studies, human PET imaging, case reports, observational studies, and randomized discontinuation trials; no new primary data are collected.
- The authors review relapse patterns after antipsychotic discontinuation, evidence on tardive dyskinesia and dopaminergic hypersensitivity, and PET-derived dose–D2 occupancy relationships.
- They use Emax equations of the form y = maximal occupancy × x/(x + ED50) to derive hyperbolic tapering schedules for six antipsychotics, with doses rounded and intended to be individualized.
Limitations
- The paper states that PET studies have relatively small sample sizes and may not capture individual variation, though the hyperbolic shape of the dose–activity curve is expected to be universal; heterogeneity in PET meta-analyses suggests interindividual differences in receptor occupancy for a given dose.
- The paper states that it is difficult to determine whether D2 occupancy linearly corresponds to withdrawal effects, and that other receptor targets such as 5HT2, 5HT1A, and cholinergic receptors may also determine withdrawal effects, particularly for clozapine.
- The text makes evident that the proposed tapering method is a hypothesis not yet tested in randomized controlled trials; the authors explicitly state that it should be tested in further tapering trials, and the figures’ time frames are described as theoretical, based on few small studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
14 Valid · 3 Not valid · 35 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis in Patients With Schizophrenia
What the sources say
- Not checked — no full text of the sourcecites [3] Viguera, 1997, Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment, Arch Gen Psychiatry. source
- Not checked — no full text of the sourcecites [56] Leucht, 2012, Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis, Lancet. source
- Not checked — no full text of the sourcecites [57] Wunderink, 2013, Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial, JAMA Psychiatry. source
- Not checked — no full text of the sourcecites [58] Mayoral-van Son, 2016, Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study, J Clin Psychiatry. source
- Disputedcites [59] Chen, 2010, Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial, BMJ. sourceExperimental — accuracy not yet measured
The Results (Primary outcome: relapse; page not provided) report that only 23 of 83 relapses occurred within 60 days of randomisation; 60 occurred later. The Methods (Statistical analysis; page not provided) identify those first 60 days as the period when relapse might be related to switching medication. The reported relapses therefore did not occur predominantly around drug cessation. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [7] Moncrieff, 2015, Antipsychotic maintenance treatment: time to rethink, PLoS Med. sourceExperimental — accuracy not yet measured
The Evidence for Maintenance Therapy section says antipsychotic withdrawal may make relapse more likely in people with schizophrenia. It does not describe persistently increased presynaptic DSC or an interaction with elevated postsynaptic sensitivity; searches for those mechanisms found no supporting passage. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [23] Chouinard, 2017, Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy, Psychother Psychosom. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Meta-analysis of molecular imaging studies in schizophrenia found increased D2/D3 receptor availability only in those subjects who had been exposed to antipsychotic medication but not in antipsychotic-naïve patients.38”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [38] Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch Gen Psychiatry. source
The Dopamine receptors section (p. 6) reports a significant difference in D2/3 receptor availability in studies including previously treated patients, but no significant difference in studies exclusively of antipsychotic-naïve patients. The Methodological considerations section (p. 8) likewise says the small elevation was not present in drug-naïve patients, while cautioning that those analyses had reduced power. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Schizophrenia is attributed to increased presynaptic dopaminergic synthesizing capacity (DSC)54”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [54] McCutcheon, 2018, Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis, Schizophr Bull. sourceExperimental — accuracy not yet measured
The Results (Studies of the Whole Striatum; page unavailable) report elevated presynaptic dopamine function in people with schizophrenia, including a significant elevation in studies using labeled L-DOPA. But the paper does not establish that increased dopamine synthesis capacity causes schizophrenia; the Discussion (The Anatomical Locus of Dopaminergic Dysfunction in Psychosis; page unavailable) says causality remains to be established. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In animals, dopaminergic blockade leads to dopaminergic hypersensitivity.35,36”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [35] Samaha, 2007, “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time, J Neurosci. source
The Introduction describes antipsychotics as antidopaminergic treatment and reports increased responses to dopamine agonists in laboratory animals after chronic treatment. The Discussion also reports dopamine supersensitivity during ongoing haloperidol treatment in animals. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [36] Joyce, 2001, D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period, Synapse source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
41 more claims · 6 with their cited sources checked
Create a free account to see all 71 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Horowitz-Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,9,15”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredIn the citing paper
“The Horowitz–Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,11,13”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Table: Table 1. Case studies reporting psychotic symptoms following abrupt cessation of dopamine antagonists prescribed for reasons other than treating psychosis in patients with no history of primary psychotic symptoms”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Eight case reports describe psychotic symptoms arising in 13 patients with no history of psychosis after the abrupt withdrawal of dopamine antagonists (table 1).”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“26 M BPAD with brief DIP and no other psychotic symptoms | Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“Table: Table 2 Randomized controlled trials examining discontinuation (DS) groups vs maintained (MT) groups (n.s. = no significant difference; N/A = not available)”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“however, this last study was not randomized, meaning selection bias is possible”
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Self-citationHowes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
Research works printed but not linked: 4
- McGorry, 2013, Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more, JAMA Psychiatry., 70, 898, 10.1001/jamapsychiatry.2013.264 · DOI · Paper page
- Seeman, 2014, Yes, Breast is best but taper domperidone when stopping (e-letter), Br J Gen Pract.
- American Psychiatric Association, 2020, Guideline statements and implementation., 312
- Lehman, 2004, Practice guideline for the treatment of partients with schizophrenia, Am J Psychiatry, 161, 1
Cited by
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Moncrieff, J., Crellin, N., Stansfeld, J., Cooper, R., Marston, L., Freemantle, N., Lewis, G., Hunter, R., Johnson, S., Barnes, T., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00258-4 · Cited by 90
Self-citationINTEGRATE: international guidelines for the algorithmic treatment of schizophrenia
McCutcheon, R. A., Pillinger, T., Varvari, I., Halstead, S., Ayinde, O. O., Crossley, N. A., Correll, C. U., Hahn, M., Howes, O. D., Kane, J. M., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00031-8 · Cited by 115
Self-citationThe expanding role of somatostatin analogs in the management of neuroendocrine tumors.
Wolin, E. M. (2012) · Europe PMC (PubMed Central) · Cited by 126
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Self-citationOstuzzi, G., Vita, G., Bertolini, F., Tedeschi, F., Luca, B. D., Gastaldon, C., Nosè, M., Papola, D., Purgato, M., Giovane, C. D., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00158-4 · Cited by 79
The Health Costs of Cost-Sharing
Chandra, A., Flack, E., & Obermeyer, Z. (2021) · National Bureau of Economic Research · doi:10.3386/w28439 · Cited by 118
Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac138 · Cited by 58
The Health Costs of Cost Sharing
Chandra, A., Flack, E., & Obermeyer, Z. (2024) · The Quarterly Journal of Economics · doi:10.1093/qje/qjae015 · Cited by 92
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
“Discontinuation strategies: For antipsychotic discontinuation, no evidence exists that gradual tapering decreases the risk of DS, although some recommend gradual and slowly (in months, possibly hyperbolic) tapering over quicker or abrupt discontinuation (Supplementary Text) [51, 56].”
BackgroundSelf-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 63
“If so, this finding would support suggestions that ultra-long tapers are necessary when stopping OAs in order to reduce relapse risk even further [154].”
ResultBlackman, G., Oloyede, E., Horowitz, M., Harland, R., Taylor, D., MacCabe, J., & McGuire, P. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 48
Self-citationCrellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 55
“However, there is a need for guidance on the best approach; current evidence suggests any reduction should be gradual and individualised to each patient to minimize risk of relapse [45, 48].”
BackgroundSuccessful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
Liu, C., Hsieh, M. H., Chien, Y., Liu, C.-M., Lin, Y., Hwang, T., & Hwu, H. (2023) · Psychological Medicine · doi:10.1017/s0033291723000429 · Cited by 42
“…a better approach based on findings of association between anti-psychotic dose and D2 receptor occupancy by PET studies, to minimize negative impact of dopamine-supersensitivity and related withdrawal symptoms (Horowitz, Jauhar, Natesan, Murray, & Taylor, 2021a; Horowitz, Murray, & Taylor, 2021b).”
BackgroundChan, M. M. Y., Choi, C. X. T., Tsoi, T. C. W., Shea, C. K., Yiu, K. W. K., & Han, Y. M. Y. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.10.012 · Cited by 39
“Since neuroadaptation to antipsychotics typically occurs within six months [81,82], potential participants who took antipsychotic medications were included only if the dosage of the medication remained unchanged for six months or more before the experimental period.”
Stupak, R., & Dobroczyński, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126625 · Cited by 39
“However, from the utility point of view of clinicians and patients, particular nerological and biological mechanisms are secondary, even though they may be also important, especially for understanding the effects of long-term exposure to drugs and withdrawal [69].”
BackgroundAdverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00014-1 · Cited by 35
Han, Y. M. Y., Chan, M. M. Y., Shea, C. K., Mo, F. Y. M., Yiu, K. W. K., Chung, R. C. K., Cheung, M., & Chan, A. S.-Y. (2023) · Autism · doi:10.1177/13623613231169547 · Cited by 34
“In view of the fact that the neuroadaptation to antipsychotics typically occurs within 6 months (Gupta et al., 2018; Horowitz et al., 2021), potential participants who were prescribed with antipsychotic medications would only be included if the dosage of the medication remained unchanged for 6 months or more before th…”
InfluentialHow to reduce and stop psychiatric medication
Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.001 · Cited by 26
Self-citationMcCutcheon, R. A., Taylor, D. M., Rubio, J. M., Nour, J., Pillinger, T., Murray, R. M., & Jauhar, S. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad139 · Cited by 27
“12,18 Recent recommendations regarding medication reduction have suggested a prolonged”
BackgroundSelf-citationMorant, N. J., Long, M., Jayacodi, S., Cooper, R. E., Akther-Robertson, J., Stansfeld, J. L., Horowitz, M. A., Priebe, S., & Moncrieff, J. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102135 · Cited by 31
Self-citationThe experiences of 585 people when they tried to withdraw from antipsychotic drugs
Read, J. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100421 · Cited by 31
“Two recent papers explain the practicalities of reducing antipsychotics carefully so as to minimise withdrawal effects (Horowitz et al., 2021; Horowitz et al., 2022).”
BackgroundAntipsychotic dose reduction compared to dose continuation for people with schizophrenia
Rodolico, A., Siafis, S., Bighelli, I., Samara, M. T., Hansen, W., Salomone, S., Aguglia, E., Cutrufelli, P., Bauer, I. O. B., Bäckers, L., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014384.pub2 · Cited by 36
Outcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22
Gangadin, S. S., de Beer, F., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., de Haan, L., Kikkert, M., Koops, S., van Os, J., et al. (2025) · World Psychiatry · doi:10.1002/wps.21315 · Cited by 28
“It has been suggested that, when antipsychotics are tapered more gradually, the relapses are more evenly distributed over time 16 .”
Tackling polypharmacy in geriatric patients: Is increasing physicians’ awareness adequate?
Sutanto, H. (2025) · Archives of Gerontology and Geriatrics Plus · doi:10.1016/j.aggp.2025.100185 · Cited by 39
Tapering antipsychotic medication: practical considerations
Horowitz, M. A., Moncrieff, J., de Haan, L., Bogers, J. P. A. M., Gangadin, S. S., Kikkert, M., Veling, W., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721003299 · Cited by 30
“A reasonable approach, therefore, is to start with a small decrease in dose, perhaps equal to 5–10 percentage of D2 receptor occupancy [equivalent to about a 25% dose reduction, depending on the starting dose (Horowitz et al., 2021)], monitor the effects on the patient for approximately two months and then proceed bas…”
BackgroundSelf-citationAdverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · doi:10.48350/165893 · Cited by 24
Ben‐Azu, B., Adebayo, O. G., Fokoua, A. R., Onuelu, J. E., Asiwe, J. N., Moke, E. G., Omogbiya, I. A., Okpara, O. L., Okoro, J. E., Oghenevwerutevwe, O. M., et al. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100122 · Cited by 24
Cooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
“Uses guidance on hyperbolic antidepressant and antipsychotic withdrawal [18, 32] Has not done this so far but would consider changing medications in future with half-life as guide.”
BackgroundSelf-citationHorowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 23
“Trials using a discontinuation design may not evidence about the pros and cons of maintenance treatment per se because of [25 && ,31] is consistent with a withdrawal-related effect on symptom occurrence or relapse.”
BackgroundMethodSelf-citationBrandt, L., Ritter, K., Schneider‐Thoma, J., Siafis, S., Montag, C., Ayrilmaz, H., Bermpohl, F., Hasan, A., Heinz, A., Leucht, S., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00008-1 · Cited by 21
Withdrawal-associated relapse is a potential source of bias
Horowitz, M. A., Murray, R. M., & Taylor, D. M. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00250-9 · Cited by 18
Self-citationMental Health Staff’s Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study
Roed, K., Buus, N., Nielsen, J., Christensen, P. S., & Midtgaard, J. (2023) · Qualitative Health Research · doi:10.1177/10497323231195821 · Cited by 17
“However, these guidelines do not provide procedures on how to reduce or discontinue antipsychotic medication past stabilization phases (Horowitz et al., 2021).”
BackgroundMethodThe Kraepelian concept of schizophrenia: Dying but not yet dead
Murray, R. M., & Quattrone, D. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.12.005 · Cited by 17
Self-citationDopamine partial agonists: a discrete class of antipsychotics
Taylor, D. M., Chithiramohan, R. N., Grewal, J., Gupta, A., Hansen, L. K., Reynolds, G. P., & Pappa, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2151473 · Cited by 17
Self-citationEserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15
Bergström, T. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111099 · Cited by 20
Boland, M., Higgins, A., Beecher, C., Bracken, P., Burn, W., Cody, A., Framer, A., Gronlund, T., Horowitz, M., Huff, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088266 · Cited by 14
Self-citationKoops, S., Allott, K., de Haan, L., Chen, E. Y. H., Hui, C. L. M., Killackey, E. J., Long, M., Moncrieff, J., Sommer, I. E., Stürup, A. E., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad112 · Cited by 15
“15,16,28 Second, studies evaluating long-term outcomes are scarce.”
BackgroundSelf-citationSchlier, B., Buck, L., Müller, R., Lincoln, T. M., Bott, A., & Pillny, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102291 · Cited by 14
“22 Aiming to gain a better understanding of the risks and bene fi ts of antipsychotic maintenance treatment vs. discontinuation for functional recovery, we performed this meta-analysis (1) to update previous meta-analyses on the overall effect of antipsychotic maintenance treatment vs.…”
MethodAhola, I., Raijada, D. K., Cornett, C., Boetker, J. P., Rantanen, J., & Genina, N. (2024) · Advanced Materials · doi:10.1002/adma.202403852 · Cited by 15
Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related Relapse
Horowitz, M. A., Murray, R. M., & Taylor, D. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab146 · Cited by 11
Self-citationO’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198463 · Cited by 12
Self-citationThe role of pharmacists in supporting service users to optimise antipsychotic medication
Howe, J., & Lindsey, L. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01630-9 · Cited by 12
“…then take control of their medication decisions, without the knowledge of their practitioners [24, 25]. service users are often unaware of withdrawal effects or the need to taper [43], abrupt discontinuation can increase relapse rates [44, 45] or withdrawal symptoms leading to unintended harm [13].”
BackgroundGoldberg, J. F., McIntyre, R. S., Swartz, H. A., Freeman, M. P., Mago, R., Citrome, L., Rosenblat, J. D., Thase, M. E., Tohen, M. F., Vieta, E., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0043 · Cited by 16
Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06554-4 · Cited by 10
“(Horowitz et al. 2021).”
Kane, J. M., Agid, O., Castle, D. J., Citrome, L., Fagiolini, A. M., Kishimoto, T., Larrauri, C. A., Leucht, S., Rubio, J. M., Sajatovic, M., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00838-3 · Cited by 20
Davidson, M., & Carpenter, W. T. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad145 · Cited by 14
“39,69 An alternative explanation for rapid worsening upon drug discontinuation is the possibility that antipsychotic drugs with intrinsic anticholinergic effects produce cholinergic re-bound upon discontinuation, which manifests as general malaise and can be mistaken for symptom worsening.”
BackgroundMølgaard, S. N., Nielsen, M. Ø., Roed, K., & Nielsen, J. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05699-y · Cited by 10
“During recent years, an increased number of studies have focused on antipsychotic dose reduction [11–15] and deprescribing guidelines have also been published [16, 17].”
BackgroundBergström, T., Seikkula, J., Köngäs‐Saviaro, P., Taskila, J. J., & Aaltonen, J. (2022) · Psychosis · doi:10.1080/17522439.2022.2134444 · Cited by 14
“It should be noted that OD did not include systematic deprescribing practice and it may be challenging to discontinue already-commenced neuroleptic medication (Horowitz et al., 2021), especially if neuroleptic maintenance treatment has been going on for many years (Tiihonen et al., 2018).”
BackgroundPredictors of successful discontinuation of antipsychotics and antidepressants
Lincoln, T. M., Sommer, D., Quazzola, M., Witzgall, T., & Schlier, B. (2021) · Psychological Medicine · doi:10.1017/s0033291721005146 · Cited by 13
“Thus, the most promising route to successful discontinuation of AP seems to be leaving time to adjust, which aligns both with expert recommendations (Horowitz et al., 2021) and with reported experiences from peer-supported clinical practice that indicate that ‘adjusting the taper to the individual’…”
BackgroundLong-term effectiveness of antipsychotics
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291721001732 · Cited by 9
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia
Horowitz, M. A., Macaulay, A., & Taylor, D. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3400 · Cited by 10
Self-citationRead, J. (2022) · Journal of Mental Health · doi:10.1080/09638237.2022.2069708 · Cited by 10
“A related, but rarely discussed, the issue is the need for information about how to successfully withdraw from these medications (Cooper et al., 2020b; Guy et al., 2019; Horowitz et al., 2021; Larsen-Barr et al., 2018; Larsen-Barr & Seymour, 2021; Moncrieff et al., 2020; Read, 2022).”
Helping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 11
“This may be because gradual cessation allows neuro-adaptations accumulated in response to the presence of antipsychotics to resolve while medication is slowly reduced 12 .”
InfluentialSelf-citationKing, S. R., Allan, M., & Lindsey, L. (2022) · Psychosis · doi:10.1080/17522439.2022.2141841 · Cited by 8
“Hyperbolic reductions, with increasingly smaller sequential increments of 25–50% previous dose, are advocated (Horowitz et al., 2021).”
BackgroundPsychiatric Manifestations of Withdrawal Following Domperidone Used as a Galactagogue
Majdinasab, E. J., Haque, S., Stark, A., Krutsch, K., & Hale, T. W. (2022) · Breastfeeding Medicine · doi:10.1089/bfm.2022.0190 · Cited by 8
“Hor-owitz et al 21 suggest that a hyperbolic taper may be effective in these cases.”
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7
“16 Finally, we aimed to devise dose reduction regimens that would fit the pre-determined constraints of RODOC.”
BackgroundMethodInfluentialSelf-citationHung, A., Wilson, L. E., Smith, V. A., Pavon, J. M., Sloan, C. E., Hastings, S. N., & Maciejewski, M. L. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19013 · Cited by 8
Aga, V. M. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.11.003 · Cited by 10
Antipsychotic maintenance treatment versus dose reduction: how the story continues
Sommer, I. E., Horowitz, M. A., Allott, K., Speyer, H., & Begemann, M. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00230-9 · Cited by 8
“6,8 Although the work from Ostuzzi and colleagues 1 provided important information, the issue of slow versus swift tapering is not yet settled, as there is a scarcity of RCTs that provide very gradual tapering over several months.”
BackgroundSelf-citationNot So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important
Horowitz, M. A., O’Neill, J., Berna, F. S., & Taylor, D. M. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf163 · Cited by 8
Self-citationJobe, L. B., Mårtensson, S., & Düring, S. W. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2023.2277820 · Cited by 7
“Therefore, a gradual tapering approach may be a suitable method to minimise the risk of relapse [31].”
MethodAftab, A. (2024) · Psychological Medicine · doi:10.1017/s003329172400312x · Cited by 5
“An important consideration here is that there is a scarcity of established guidelines and practical ‘ know-how ’ when it comes to dose-reduction and discontinuation of antipsychotics (see Horowitz, Jauhar, Natesan, Murray, & Taylor, 2021, for a proposed method of tapering antipsychotics).”
Does relapse cause illness progression in first-episode psychosis? A review
Kennedy, K. P., Zito, M. F., & Marder, S. R. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.07.038 · Cited by 6
Goldberg, J. F., Swartz, H. A., McIntyre, R. S., Mago, R., Malhi, G. S., Jha, M. K., Berk, M., Kasper, S. F., Freeman, M. P., Gitlin, M. J., et al. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10580 · Cited by 6
Wand, T. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2476156 · Cited by 6
“The severity of psychosis following clozapine withdrawal has also been noted to exceed that of the presenting condition before clozapine treatment (Horowitz, Jauhar, et al., 2021).”
InfluentialUnbalanced appraisal of psychosocial versus antipsychotic literature
Horowitz, M. A., Munkholm, K., & Moncrieff, J. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00153-5 · Cited by 4
Self-citationLiu, C., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., & Hwu, H. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2440 · Cited by 4
“that it will be easier to taper a larger fraction of medication at higher dose levels, while it will be safer to only cut off a much smaller fraction of dose at the lower dose level [42].”
InfluentialCaffeine-Induced Psychosis: A Case Report and Review of Literature
Mannix, D., Mulholland, K., & Byrne, F. (2024) · Cureus · doi:10.7759/cureus.66306 · Cited by 7
“…article published in the Schizophrenia Bulletin, which describes increased post-synaptic receptor availability and affinity in people who have been exposed to long-term antipsychotics and then have same withdrawn, causing a relapse of psychosis via drug-induced dopaminergic hypersensitivity [16].”
BackgroundLiu, C.-I., Liu, C., Chiu, H.-H., Chuang, C.-C., Hwang, T., Hsieh, M. H., Chien, Y., Lin, Y., Yen, K., & Liu, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724002356 · Cited by 4
“The procedure is similar to that proposed by Horowitz et al., considering the D2 blockade dynamics (Costardi, Gadelha, & Bressan, 2021; Horowitz, Jauhar, Natesan, Murray, & Taylor, 2021a; Horowitz, Murray, & Taylor, 2021b).”
MethodO'Brien, D., Healy, A. M., Harkin, A., & Cadogan, C. A. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70082 · Cited by 5
Maintenance antipsychotic trials and the effect of withdrawal
Munkholm, K., Horowitz, M. A., & Moncrieff, J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01467-2 · Cited by 4
Self-citationWilson, M., Harris, M., Pereira, M., Buckle, J., Forshall, E., Murphy, T., Thompson, A. D., Kavanagh, G., & Whale, R. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.004 · Cited by 6
Jeffares, I., Friars, D., Plapp, H. M., Allott, K., Cadogan, C. A., Keating, D., Mooney, C., O’Connor, K., & O'Donoghue, B. N. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf181 · Cited by 3
“The hyperbolic method was recommended in two literature reviews/expert consensus papers 11 , 72 and specifically employed in one clinical study, 25 where four dose reductions were made over a two-year period.”
Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation
Oruch, R., Rajab, H. A., Elderbi, M., Pryme, I. F., Fasmer, O. B., & Lund, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228125 · Cited by 7
“This is necessary to avoid acute withdrawal syndrome and rapid relapse of psychosis [39].”
Standal, K., Solbakken, O. A., Benth, J. Š., Abbass, A. A., & Heiervang, K. S. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251390930 · Cited by 4
“(Bai et al., 2020; Cai et al., 2023; Ceraso et al., 2020; Correll et al., 2018; Croatto et al., 2023; Davies & Read, 2019; Hengartner, 2020; Horowitz et al., 2021; Jakobsen et al., 2020; Levenberg & Cordner, 2022; Moncrieff et al., 2020; Sinyor et al., 2020) and represent important concerns for…”
Langzeittherapie der Schizophrenie
Huhn, M., Schneider‐Thoma, J., & Leucht, S. (2022) · PSYCH up2date · doi:10.1055/a-1239-5941 · Cited by 3
“Hier unterscheiden sich Präparate deutlich.”
BackgroundInfluentialPotla, S., AlQabandi, Y., Nandula, S. A., Boddepalli, C. S., Gutlapalli, S. D., Lavu, V. K., Abdelwahab, R. A. M., Huang, R., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.34746 · Cited by 5
“Relapse rates remained the dominant outcome criterion in assessing the efficacy of antipsychotic treatment methods [4].”
InfluentialBickerton, L., & Kuriakose, J. L. (2023) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2023.10.001 · Cited by 5
O’Neill, J. R., Jameson, A., McLean, S. L., Dixon, M., Cardno, A. G., & Lawrence, C. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239543 · Cited by 4
“It is vital that this reduction takes place in a steady and hyperbolic manner to avoid withdrawal symptoms as a confounding effect (Horowitz et al., 2021; O’Neill et al., 2023).”
BackgroundMethodRead, J. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12551 · Cited by 3
Li, L., Le, T. H., Kim, W., Odkhuu, S., Kang, C. Y., Setiani, A., Jeon, E., Rami, F. Z., & Chung, Y. (2025) · Schizophrenia · doi:10.1038/s41537-025-00592-3 · Cited by 5
“In discontinuation RCTs, the lowest doses before complete cessation were 1 ~ 3 mg or 5 ~ 20 mg/day of haloperidol equivalent (37.5 ~ 112.5 mg/day or 187.5 ~ 750 mg/day of chlor-promazine equivalent) 14 , or were not available 15 .”
InfluentialLiu, C.-I., Liu, C., Hsieh, M. H., Lin, Y., Chen, W., Hwang, T., Yen, K., & Liu, C. (2025) · Psychological Medicine · doi:10.1017/s0033291725101591 · Cited by 2
“Studies examining long-term tapering suggest that tapering may carry an equal risk of relapse compared to maintenance treatment (MT), while simultaneously resulting in improvements in cognitive and functional outcomes (Begemann et al., 2020; Horowitz, Jauhar, Natesan, Murray, & Taylor, 2021).”
Polypharmacy with Multi-Mechanism Drugs: A Hidden Risk for Drug Interactions and Adverse Effects
Briones-Aranda, A. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1013524 · Cited by 3
Aprile, S. F., Rodolico, A., Munafò, A., Bighelli, I., Caraci, F., & Leucht, S. (2026) · Schizophrenia · doi:10.1038/s41537-026-00747-w · Cited by 3
“…with pre-speci fi ed schedules 47,48 , clinician-guided discontinuation based on symptom monitoring and patient preferences 18,49 , hyperbolic tapering grounded in receptor-occupancy pharmacodynamics 50,51 , and biomarker-guided dose titration using plasma-level or D ₂ -occupancy modeling 52 .”
Takeuchi, H., & Watabe, K. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13534 · Cited by 3
Bergström, T., & Gauffin, T. (2023) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgad032 · Cited by 4
“45 These factors would explain the findings of this study as well as the previous mixed results from observational studies, but they still merit’s further research with more robust design.”
ResultHaloperidol Induced Orofacial Dyskinesia: Clinical Insights Into Buccolingual Masticatory Syndrome
Bereda, G. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71083 · Cited by 2
“Prognosis depends on the duration of antipsychotic exposure, severity of symptoms, and timing of intervention [21].”
Boland, M., Higgins, A., Beecher, C., Bracken, P. J., Burn, W., Cody, A., Framer, A., Gronlund, T. A., Horowitz, M. A., Huff, C., et al. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13649.1 · Cited by 2
Self-citationCollaborative discontinuation of antipsychotics after the first episode of psychosis
Korchia, T., Abdelhafez, H., Bretelle, A., Joober, R., & Palaniyappan, L. K. (2023) · Journal of Psychiatry and Neuroscience · doi:10.1503/220223 · Cited by 3
“4 A recent proposal advocates for hyperbolic tapering over several months; 13 the acceptability of such extended tapering in first-episode settings is yet to be evaluated.”
BackgroundMobile phone applications to support psychotropic tapering: a scoping review protocol
Boland, M., Higgins, A., Doherty, G. J., Sheaf, G., Framer, A., & Cadogan, C. A. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13501.2 · Cited by 2
“A conservative 10% dose reduction per month of the most recent dose is a common approach with some successes reported 23,24 .”
Deprescribing antipsychotics in adults with psychotic disorders – a literature review
Painter, J. M. (2023) · Mental Health Practice · doi:10.7748/mhp.2023.e1670 · Cited by 1
Schneidman, A., Roe, D., Zisman‐Ilani, Y., & Shpigelman, C. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251326293 · Cited by 2
Ahola, I., Cornett, C., Rantanen, J., Genina, N., & Amigo, J. M. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107145 · Cited by 2
Nyttingnes, O., Hofstad, T., Johnsen, E., Strømme, M. F., Markussen, S., Killackey, E. J., Rinaldi, M., Blindheim, A. A., McDaid, D., Brinchmann, B., et al. (2025) · F1000Research · doi:10.12688/f1000research.166156.1 · Cited by 1
Drug tapering in animal research: current practices and challenges
Zhang, Y., Chen, M., Jiang, T., Fu, Q., Ma, R., Nie, L., You, Y., Gao, S., & Rong, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544784 · Cited by 1
Liu, Y., Sommer, I. E., Begemann, M., Gangadin, S. S., Perry, B. I., Scheurink, T. A. W., van Beveren, N. J. M., Sommer, I. E., de Haan, L., Veling, W., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf116 · Cited by 3
“39 The mechanisms underlying movement disorders are not fully understood, and several hypotheses have been proposed.”
Metadata
- Authors
- Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D.
- Affiliations
- Goodmayes Hospital (GB)
- King's College London (GB)
- Corresponding author
- Horowitz, Mark Abie
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-23
- Volume
- 47
- Issue
- 4
- Pages
- 1116-1129
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC8266572
- OpenAlex
- W3137682600
- Semantic Scholar
- a855858cd020d93218767ac4e43fbf07848933a0
- Cited by
- 157
- References
- 127
- Citations by year
- 2026: 28 · 2025: 33 · 2024: 24 · 2023: 32 · 2022: 24 · 2021: 15
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Funders
- North East London NHS Foundation Trust
- Royal College of Physicians of Edinburgh
- National Institute for Health Research Biomedical Research Centre
- South London and Maudsley NHS Foundation Trust
- King’s College London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- antipsychotic tapering, antipsychotic discontinuation
- MeSH terms
- Drug Administration Schedule, Female, Humans, Male, Recurrence, Schizophrenia, Antipsychotic Agents, Risk Assessment, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.